Literature DB >> 11931347

(N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Terry W Moody1, Robert T Jensen, Mati Fridkin, Illana Gozes.   

Abstract

The effects of a (N-stearyl, Norleucine17) vasoactive intestinal peptide hybrid ((SN)VIPhybrid) on cells stably transfected with VPAC,, VPAC2, or PAC1 receptors were investigated. (SN)VIPhybrid inhibited specific 125I-VIP binding to membranes derived from CHO cells transfected with VPAC, or VPAC2 receptors with high affinity (IC50 = 30 and 50 nM). (SN)VIPhyb inhibited specific 125I-PACAP-27 binding to membranes derived from NIH/3T3 cells transfected with PAC1 receptors with high affinity (IC50 = 65 nM). PACAP-27 caused cAMP elevation in NIH/3T3 cells transfected with PAC1 receptors and the increase cAMP caused by pituitary adenylated cyclase (PACAP) was inhibited by (SN)VIPhyb. Also, the increase in cAMP caused by VIP using CHO cells transfected with VPAC1 or VPAC2 receptors was antagonized by (SN)VIPhyb. These results indicate that (SN)VIPhyb is an antagonist for VPAC1, VPAC2, and PAC1 receptors.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11931347     DOI： 10.1385/JMN:18:1-2:29

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   3.444


  42 in total

1.  (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.

Authors:  H Zia; J Leyton; M Casibang; V Hau; D Brenneman; M Fridkin; I Gozes; T W Moody
Journal:  Life Sci       Date:  2000       Impact factor: 5.037

2.  An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.

Authors:  I Gozes; S K McCune; L Jacobson; D Warren; T W Moody; M Fridkin; D E Brenneman
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

3.  Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.

Authors:  I Gozes; G Lilling; R Glazer; A Ticher; I E Ashkenazi; A Davidson; S Rubinraut; M Fridkin; D E Brenneman
Journal:  J Pharmacol Exp Ther       Date:  1995-04       Impact factor: 4.030

4.  Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung.

Authors:  L Y Korman; D N Carney; M L Citron; T W Moody
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

5.  Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.

Authors:  H Zia; T Hida; S Jakowlew; M Birrer; Y Gozes; J C Reubi; M Fridkin; I Gozes; T W Moody
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

6.  Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury.

Authors:  D M Jaworski
Journal:  Cell Tissue Res       Date:  2000-05       Impact factor: 5.249

7.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

8.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

Authors:  T Ishihara; R Shigemoto; K Mori; K Takahashi; S Nagata
Journal:  Neuron       Date:  1992-04       Impact factor: 17.173

9.  Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma.

Authors:  M S O'Dorisio; D J Fleshman; S J Qualman; T M O'Dorisio
Journal:  Regul Pept       Date:  1992-02-18

10.  Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels.

Authors:  M Lee; R T Jensen; S C Huang; G Bepler; L Korman; T W Moody
Journal:  Peptides       Date:  1990 Nov-Dec       Impact factor: 3.750
View more
  9 in total

1.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

2.  Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice.

Authors:  John P Vu; Mulugeta Million; Muriel Larauche; Leon Luong; Joshua Norris; James A Waschek; Charalabos Pothoulakis; Joseph R Pisegna; Patrizia M Germano
Journal:  J Mol Neurosci       Date:  2014-01-07       Impact factor: 3.444

3.  Effects of VPAC1 activation in nucleus ambiguus neurons.

Authors:  Florin Liviu Gherghina; Andrei Adrian Tica; Elena Deliu; Mary E Abood; G Cristina Brailoiu; Eugen Brailoiu
Journal:  Brain Res       Date:  2016-12-30       Impact factor: 3.252

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP).

Authors:  Illana Gozes
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-16       Impact factor: 5.555

6.  Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons.

Authors:  Ulrikke Voss; Elin Sand; Per M Hellström; Eva Ekblad
Journal:  BMC Gastroenterol       Date:  2012-04-01       Impact factor: 3.067

Review 7.  Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system.

Authors:  Mari Iwasaki; Yasutada Akiba; Jonathan D Kaunitz
Journal:  F1000Res       Date:  2019-09-12

8.  Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library.

Authors:  Bo Tang; Zhexu Li; Dingde Huang; Lei Zheng; Qianwei Li
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

9.  A Molecular Dynamics Study of Vasoactive Intestinal Peptide Receptor 1 and the Basis of Its Therapeutic Antagonism.

Authors:  Dorota Latek; Ingrid Langer; Krystiana Krzysko; Lukasz Charzewski
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.